What Is The Evidence From Research On The Effects Of Probiotics On Depression?

Research on probiotics and depression shows mixed results. Some specific probiotic strains may improve depressive symptoms, sexual function in depressed women, and cognitive function, but evidence is inconsistent and strain-specific effects vary.

Very low

Low

Moderate

High

Certainty not assessed

This analysis does not carry a graded certainty rating. Read the limitations section before drawing conclusions.

What the research shows

High-quality randomized controlled trials (RCTs) and meta-analyses provide mixed evidence on probiotics for depression. Bifidobacterium bifidum combined with SSRIs improved sexual function and depressive symptoms in women. Lactiplantibacillus plantarum PS128 showed no significant effect on depressive symptoms in a small RCT. Limosilactobacillus reuteri did not improve depressive symptoms in overweight patients with inflammation, though a biomarker (formic acid) was linked to response. A meta-analysis found probiotics may improve cognition but had negligible effect on depressive symptoms overall. Low-evidence studies and reviews suggest potential benefits of various strains including Bifidobacterium longum and Lactobacillus spp., but more standardized, larger trials are needed. Safety appears acceptable but long-term effects require further study.

Best studied probiotic strains

Bifidobacterium bifidum

High-quality RCT (PMID 38216917) showed that an 8-week probiotic supplement containing Bifidobacterium bifidum plus SSRIs improved sexual function, sexual satisfaction, and depressive symptoms in women with depression.

Used as adjunct to SSRIs; effects on sexual function and depression severity observed; specific to women under SSRI treatment.

Lactiplantibacillus plantarum PS128

High-quality RCT (PMID 39232392) found no significant difference in depressive symptoms compared to placebo after 8 weeks in patients with major depressive disorder, though some potential effects on gut microbiota taxa were noted.

No significant clinical improvement in depression; further research with larger samples needed.

Limosilactobacillus reuteri

High-quality RCT (PMID 40484149) showed no significant antidepressant effect in overweight depressed patients with inflammation, but changes in fecal formic acid correlated with symptom improvement.

No overall effect on depression; possible biomarker identified; more research needed.

Bifidobacterium longum

High-quality RCT secondary analysis (PMID 39089652) suggested probiotics containing Bifidobacterium longum may improve liver-related parameters in depressed patients, with potential implications for comorbidities.

No direct depression symptom improvement reported; focus on liver health in depression.

View products containing microorganisms linked to this analysis

Who may benefit

Women with depression undergoing SSRI treatment (for sexual function and depressive symptoms) Patients with depression interested in adjunctive probiotic therapy Individuals with depression and comorbid liver steatosis (potential liver benefits) Patients seeking cognitive improvements alongside depression treatment

Safety

Probiotics studied were generally well tolerated with no major safety concerns reported. However, long-term safety data and effects in diverse populations remain limited.

Limitations

Evidence is limited by heterogeneity in strains, dosages, intervention durations, and outcome measures. Many studies have small sample sizes or short durations. Some findings are preliminary or secondary analyses. Effects appear strain-specific and may not generalize. More large-scale, standardized RCTs are needed to confirm efficacy and safety.

PubMed sources

Study	Type	Year	PMID
The Role of Gut Microbiota in Anxiety, Depression, and Other Mental Disorders as Well as the Protective Effects of Dietary Components. Nutrients	Research Study	2023	37513676
Adjuvant administration of probiotic effects on sexual function in depressant women undergoing SSRIs treatment: a double-blinded randomized controlled trial. BMC psychiatry	Randomized Controlled Trial	2024	38216917
Gut emotions - mechanisms of action of probiotics as novel therapeutic targets for depression and anxiety disorders. CNS & neurological disorders drug targets	Systematic Review	2014	25470391
The effects of Lactobacillus plantarum PS128 in patients with major depressive disorder: an eight-week double-blind, placebo-controlled study. Asian journal of psychiatry	Randomized Controlled Trial	2024	39232392
The psychobiotic revolution: comprehending the optimistic role of gut microbiota on gut-brain axis during neurological and Gastrointestinal (GI) disorders. World journal of microbiology & biotechnology	Research Study	2025	41129047
Efficacy of spp. Interventions to Modulate Mood Symptoms: A Scoping Review of Clinical Trials. International journal of molecular sciences	Research Study	2025	40869419
From isoniazid to psychobiotics: the gut microbiome as a new antidepressant target. British journal of hospital medicine (London, England : 2005)	Research Study	2019	30860919
Probiotics may be useful for drug-induced liver dysfunction in patients with depression - A secondary analysis of a randomized clinical trial. Clinical nutrition ESPEN	Randomized Controlled Trial	2024	39089652
Effect of probiotic supplementation on cognition and depressive symptoms in patients with depression: A systematic review and meta-analysis. Medicine	Meta-analysis	2023	38013351
Add-on probiotics for inflammatory depression - A double-blind randomized placebo-controlled trial. Brain, behavior, and immunity	Randomized Controlled Trial	2025	40484149